Drug Type Monoclonal antibody |
Synonyms Anti-CD4 monoclonal antibody MDX CD4, Zanolimumab (USAN/INN), HUMAX-CD4 + [4] |
Target |
Mechanism CD4 inhibitors(T-cell surface antigen CD4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06356 | Zanolimumab | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cutaneous T-Cell Lymphoma | Phase 3 | - | 01 Aug 2005 | |
Mycosis Fungoides | Phase 3 | US | 01 Jul 2005 | |
Mycosis Fungoides | Phase 3 | FR | 01 Jul 2005 | |
Mycosis Fungoides | Phase 3 | DE | 01 Jul 2005 | |
Mycosis Fungoides | Phase 3 | IT | 01 Jul 2005 | |
Mycosis Fungoides | Phase 3 | ES | 01 Jul 2005 | |
Sezary Syndrome | Phase 3 | US | 01 Jul 2005 | |
Sezary Syndrome | Phase 3 | FR | 01 Jul 2005 | |
Sezary Syndrome | Phase 3 | DE | 01 Jul 2005 | |
Sezary Syndrome | Phase 3 | IT | 01 Jul 2005 |
Phase 2 | 9 | (HD IL-2 + Zanolimumab - Melanoma) | vcjlkbounq(swrztfxosm) = dtzibjojro qzgmntbprm (lbaxlmnqtq, nicubpkadl - oottbagxhs) View more | - | 11 Dec 2012 | ||
(HD IL-2 + Zanolimumab - Renal Cell) | vcjlkbounq(swrztfxosm) = skrucunmqr qzgmntbprm (lbaxlmnqtq, dzvjirdhwk - oebdrtondg) View more |